A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys.
Identifieur interne : 000192 ( PubMed/Corpus ); précédent : 000191; suivant : 000193A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys.
Auteurs : Ji-Young Min ; Leatrice Vogel ; Yumiko Matsuoka ; Bin Lu ; David Swayne ; Hong Jin ; George Kemble ; Kanta SubbaraoSource :
- Journal of virology [ 1098-5514 ] ; 2010.
English descriptors
- KwdEn :
- Animals, Antibodies, Neutralizing (immunology), Antibodies, Viral (immunology), Chick Embryo, Chickens, Chlorocebus aethiops, Disease Models, Animal, Female, Ferrets, Hemagglutinin Glycoproteins, Influenza Virus (administration & dosage), Hemagglutinin Glycoproteins, Influenza Virus (genetics), Hemagglutinin Glycoproteins, Influenza Virus (immunology), Humans, Influenza A Virus, H7N7 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (genetics), Influenza Vaccines (immunology), Influenza, Human (immunology), Influenza, Human (prevention & control), Influenza, Human (virology), Male, Mice, Mice, Inbred BALB C, Neuraminidase (administration & dosage), Neuraminidase (genetics), Neuraminidase (immunology), Vaccines, Attenuated (administration & dosage), Vaccines, Attenuated (adverse effects), Vaccines, Attenuated (genetics), Vaccines, Attenuated (immunology), Viral Proteins (administration & dosage), Viral Proteins (genetics), Viral Proteins (immunology).
- MESH :
- chemical , administration & dosage : Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Neuraminidase, Vaccines, Attenuated, Viral Proteins.
- chemical , adverse effects : Influenza Vaccines, Vaccines, Attenuated.
- chemical , genetics : Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Neuraminidase, Vaccines, Attenuated, Viral Proteins.
- chemical , immunology : Antibodies, Neutralizing, Antibodies, Viral, Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Neuraminidase, Vaccines, Attenuated, Viral Proteins.
- immunology : Influenza A Virus, H7N7 Subtype, Influenza, Human.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Animals, Chick Embryo, Chickens, Chlorocebus aethiops, Disease Models, Animal, Female, Ferrets, Humans, Male, Mice, Mice, Inbred BALB C.
Abstract
A live attenuated H7N7 candidate vaccine virus was generated by reverse genetics using the modified hemagglutinin (HA) and neuraminidase (NA) genes of highly pathogenic (HP) A/Netherlands/219/03 (NL/03) (H7N7) wild-type (wt) virus and the six internal protein genes of the cold-adapted (ca) A/Ann Arbor/6/60 ca (AA ca) (H2N2) virus. The reassortant H7N7 NL/03 ca vaccine virus was temperature sensitive and attenuated in mice, ferrets, and African green monkeys (AGMs). Intranasal (i.n.) administration of a single dose of the H7N7 NL/03 ca vaccine virus fully protected mice from lethal challenge with homologous and heterologous H7 viruses from Eurasian and North American lineages. Two doses of the H7N7 NL/03 ca vaccine induced neutralizing antibodies in serum and provided complete protection from pulmonary replication of homologous and heterologous wild-type H7 challenge viruses in mice and ferrets. One dose of the H7N7 NL/03 ca vaccine elicited an antibody response in one of three AGMs that was completely protected from pulmonary replication of the homologous wild-type H7 challenge virus. The contribution of CD8(+) and/or CD4(+) T cells to the vaccine-induced protection of mice was evaluated by T-cell depletion; T lymphocytes were not essential for the vaccine-induced protection from lethal challenge with H7 wt viruses. Additionally, passively transferred neutralizing antibody induced by the H7N7 NL/03 ca virus protected mice from lethality following challenge with H7 wt viruses. The safety, immunogenicity, and efficacy of the H7N7 NL/03 ca vaccine virus in mice, ferrets, and AGMs support the evaluation of this vaccine virus in phase I clinical trials.
DOI: 10.1128/JVI.01305-10
PubMed: 20810733
Links to Exploration step
pubmed:20810733Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys.</title>
<author><name sortKey="Min, Ji Young" sort="Min, Ji Young" uniqKey="Min J" first="Ji-Young" last="Min">Ji-Young Min</name>
<affiliation><nlm:affiliation>LID, NIAID, NIH, Bethesda, MD 20892, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name>
</author>
<author><name sortKey="Matsuoka, Yumiko" sort="Matsuoka, Yumiko" uniqKey="Matsuoka Y" first="Yumiko" last="Matsuoka">Yumiko Matsuoka</name>
</author>
<author><name sortKey="Lu, Bin" sort="Lu, Bin" uniqKey="Lu B" first="Bin" last="Lu">Bin Lu</name>
</author>
<author><name sortKey="Swayne, David" sort="Swayne, David" uniqKey="Swayne D" first="David" last="Swayne">David Swayne</name>
</author>
<author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name>
</author>
<author><name sortKey="Kemble, George" sort="Kemble, George" uniqKey="Kemble G" first="George" last="Kemble">George Kemble</name>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20810733</idno>
<idno type="pmid">20810733</idno>
<idno type="doi">10.1128/JVI.01305-10</idno>
<idno type="wicri:Area/PubMed/Corpus">000192</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000192</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys.</title>
<author><name sortKey="Min, Ji Young" sort="Min, Ji Young" uniqKey="Min J" first="Ji-Young" last="Min">Ji-Young Min</name>
<affiliation><nlm:affiliation>LID, NIAID, NIH, Bethesda, MD 20892, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name>
</author>
<author><name sortKey="Matsuoka, Yumiko" sort="Matsuoka, Yumiko" uniqKey="Matsuoka Y" first="Yumiko" last="Matsuoka">Yumiko Matsuoka</name>
</author>
<author><name sortKey="Lu, Bin" sort="Lu, Bin" uniqKey="Lu B" first="Bin" last="Lu">Bin Lu</name>
</author>
<author><name sortKey="Swayne, David" sort="Swayne, David" uniqKey="Swayne D" first="David" last="Swayne">David Swayne</name>
</author>
<author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name>
</author>
<author><name sortKey="Kemble, George" sort="Kemble, George" uniqKey="Kemble G" first="George" last="Kemble">George Kemble</name>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
</author>
</analytic>
<series><title level="j">Journal of virology</title>
<idno type="eISSN">1098-5514</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Neutralizing (immunology)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Chick Embryo</term>
<term>Chickens</term>
<term>Chlorocebus aethiops</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Ferrets</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (administration & dosage)</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (genetics)</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (immunology)</term>
<term>Humans</term>
<term>Influenza A Virus, H7N7 Subtype (immunology)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (adverse effects)</term>
<term>Influenza Vaccines (genetics)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (immunology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Neuraminidase (administration & dosage)</term>
<term>Neuraminidase (genetics)</term>
<term>Neuraminidase (immunology)</term>
<term>Vaccines, Attenuated (administration & dosage)</term>
<term>Vaccines, Attenuated (adverse effects)</term>
<term>Vaccines, Attenuated (genetics)</term>
<term>Vaccines, Attenuated (immunology)</term>
<term>Viral Proteins (administration & dosage)</term>
<term>Viral Proteins (genetics)</term>
<term>Viral Proteins (immunology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Influenza Vaccines</term>
<term>Neuraminidase</term>
<term>Vaccines, Attenuated</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Attenuated</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Influenza Vaccines</term>
<term>Neuraminidase</term>
<term>Vaccines, Attenuated</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Influenza Vaccines</term>
<term>Neuraminidase</term>
<term>Vaccines, Attenuated</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H7N7 Subtype</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Chick Embryo</term>
<term>Chickens</term>
<term>Chlorocebus aethiops</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Ferrets</term>
<term>Humans</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A live attenuated H7N7 candidate vaccine virus was generated by reverse genetics using the modified hemagglutinin (HA) and neuraminidase (NA) genes of highly pathogenic (HP) A/Netherlands/219/03 (NL/03) (H7N7) wild-type (wt) virus and the six internal protein genes of the cold-adapted (ca) A/Ann Arbor/6/60 ca (AA ca) (H2N2) virus. The reassortant H7N7 NL/03 ca vaccine virus was temperature sensitive and attenuated in mice, ferrets, and African green monkeys (AGMs). Intranasal (i.n.) administration of a single dose of the H7N7 NL/03 ca vaccine virus fully protected mice from lethal challenge with homologous and heterologous H7 viruses from Eurasian and North American lineages. Two doses of the H7N7 NL/03 ca vaccine induced neutralizing antibodies in serum and provided complete protection from pulmonary replication of homologous and heterologous wild-type H7 challenge viruses in mice and ferrets. One dose of the H7N7 NL/03 ca vaccine elicited an antibody response in one of three AGMs that was completely protected from pulmonary replication of the homologous wild-type H7 challenge virus. The contribution of CD8(+) and/or CD4(+) T cells to the vaccine-induced protection of mice was evaluated by T-cell depletion; T lymphocytes were not essential for the vaccine-induced protection from lethal challenge with H7 wt viruses. Additionally, passively transferred neutralizing antibody induced by the H7N7 NL/03 ca virus protected mice from lethality following challenge with H7 wt viruses. The safety, immunogenicity, and efficacy of the H7N7 NL/03 ca vaccine virus in mice, ferrets, and AGMs support the evaluation of this vaccine virus in phase I clinical trials.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20810733</PMID>
<DateCompleted><Year>2010</Year>
<Month>11</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>84</Volume>
<Issue>22</Issue>
<PubDate><Year>2010</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys.</ArticleTitle>
<Pagination><MedlinePgn>11950-60</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01305-10</ELocationID>
<Abstract><AbstractText>A live attenuated H7N7 candidate vaccine virus was generated by reverse genetics using the modified hemagglutinin (HA) and neuraminidase (NA) genes of highly pathogenic (HP) A/Netherlands/219/03 (NL/03) (H7N7) wild-type (wt) virus and the six internal protein genes of the cold-adapted (ca) A/Ann Arbor/6/60 ca (AA ca) (H2N2) virus. The reassortant H7N7 NL/03 ca vaccine virus was temperature sensitive and attenuated in mice, ferrets, and African green monkeys (AGMs). Intranasal (i.n.) administration of a single dose of the H7N7 NL/03 ca vaccine virus fully protected mice from lethal challenge with homologous and heterologous H7 viruses from Eurasian and North American lineages. Two doses of the H7N7 NL/03 ca vaccine induced neutralizing antibodies in serum and provided complete protection from pulmonary replication of homologous and heterologous wild-type H7 challenge viruses in mice and ferrets. One dose of the H7N7 NL/03 ca vaccine elicited an antibody response in one of three AGMs that was completely protected from pulmonary replication of the homologous wild-type H7 challenge virus. The contribution of CD8(+) and/or CD4(+) T cells to the vaccine-induced protection of mice was evaluated by T-cell depletion; T lymphocytes were not essential for the vaccine-induced protection from lethal challenge with H7 wt viruses. Additionally, passively transferred neutralizing antibody induced by the H7N7 NL/03 ca virus protected mice from lethality following challenge with H7 wt viruses. The safety, immunogenicity, and efficacy of the H7N7 NL/03 ca vaccine virus in mice, ferrets, and AGMs support the evaluation of this vaccine virus in phase I clinical trials.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Min</LastName>
<ForeName>Ji-Young</ForeName>
<Initials>JY</Initials>
<AffiliationInfo><Affiliation>LID, NIAID, NIH, Bethesda, MD 20892, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vogel</LastName>
<ForeName>Leatrice</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Matsuoka</LastName>
<ForeName>Yumiko</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lu</LastName>
<ForeName>Bin</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Swayne</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jin</LastName>
<ForeName>Hong</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kemble</LastName>
<ForeName>George</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Subbarao</LastName>
<ForeName>Kanta</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2010</Year>
<Month>09</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C483468">hemagglutinin, human influenza A virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="C487630">NA protein, influenza A virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002642" MajorTopicYN="N">Chick Embryo</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002645" MajorTopicYN="N">Chickens</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005289" MajorTopicYN="N">Ferrets</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053126" MajorTopicYN="N">Influenza A Virus, H7N7 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>9</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2010</Year>
<Month>9</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>12</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">20810733</ArticleId>
<ArticleId IdType="pii">JVI.01305-10</ArticleId>
<ArticleId IdType="doi">10.1128/JVI.01305-10</ArticleId>
<ArticleId IdType="pmc">PMC2977864</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Vet Microbiol. 2000 May 22;74(1-2):3-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10799774</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Aug 6;27(36):4953-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19540952</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2000;145(5):1047-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10881690</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2003 Feb 1;306(1):18-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12620793</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2003 May 16;21(17-18):1974-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12706686</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2003 Oct 1;21(27-30):4430-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14505926</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Dec;77(24):13399-402</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14645595</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jan;78(2):995-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14694130</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1356-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14745020</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 Feb 21;363(9409):587-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14987882</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2004 Apr 9;53(13):284-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15071427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2004 Apr;10(4):693-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15200862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2004 Jul 2;53(25):547-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15229411</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2004 Oct 22;22(31-32):4137-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15474703</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1981 Sep;113(2):725-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7023022</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 1987 Aug 28;50(5):665-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3304656</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vet Pathol. 1994 Mar;31(2):237-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8203087</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 1996 Sep 28;348(9031):901-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8826845</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1997 Feb 1;158(3):1222-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9013963</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 1997 Jun;49(2):173-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9213392</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 1998;143(4):781-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9638147</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2004 Dec;10(12):2196-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15663860</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2005 Mar;86(Pt 3):727-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15722533</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Infect Dis. 2005 Apr;18(2):141-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15735418</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Oct;79(19):12401-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16160167</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2006 Jan;12(1):66-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16494720</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Sep;3(9):e360</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2007 Apr;7(4):267-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17363960</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Oct;81(19):10558-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17634234</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2007 Nov;14(11):1425-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17913860</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2008 Jan 17;358(3):261-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18199865</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Mar 25;26(14):1742-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18336962</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2008 May 27;105(21):7558-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18508975</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2008 Aug 15;378(1):123-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18585748</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2009 Mar 1;199(5):711-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19210163</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Mar 18;27(13):1889-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19368768</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2007 Jul;1(4):157-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19432631</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Jun 8;27(28):3744-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19464558</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2009 Dec 20;395(2):280-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19833372</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Feb;84(3):1289-301</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19906920</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2000 May 23;97(11):6108-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10801978</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000192 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000192 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:20810733 |texte= A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:20810733" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
This area was generated with Dilib version V0.6.33. |